USD 0.25
(-14.21%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 423.52 Million USD | -30.58% |
2022 | 610.08 Million USD | -21.16% |
2021 | 773.82 Million USD | -6.41% |
2020 | 826.84 Million USD | -3.56% |
2019 | 857.39 Million USD | -2.63% |
2018 | 880.59 Million USD | -2.01% |
2017 | 898.65 Million USD | 91.38% |
2016 | 469.55 Million USD | -0.22% |
2015 | 470.57 Million USD | -2.68% |
2014 | 483.52 Million USD | 62.83% |
2013 | 296.95 Million USD | 11.81% |
2012 | 265.58 Million USD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 293.2 Million USD | -19.86% |
2024 Q1 | 365.86 Million USD | -13.61% |
2023 Q2 | 515.12 Million USD | -4.35% |
2023 Q4 | 423.52 Million USD | -8.01% |
2023 FY | 423.52 Million USD | -30.58% |
2023 Q1 | 538.54 Million USD | -11.73% |
2023 Q3 | 460.42 Million USD | -10.62% |
2022 Q1 | 745.93 Million USD | -3.6% |
2022 FY | 610.08 Million USD | -21.16% |
2022 Q4 | 610.08 Million USD | 0.21% |
2022 Q3 | 608.83 Million USD | -11.35% |
2022 Q2 | 686.78 Million USD | -7.93% |
2021 Q4 | 773.82 Million USD | -9.02% |
2021 Q2 | 808.61 Million USD | 2.71% |
2021 Q3 | 850.51 Million USD | 5.18% |
2021 FY | 773.82 Million USD | -6.41% |
2021 Q1 | 787.3 Million USD | -4.78% |
2020 Q4 | 826.84 Million USD | 1.83% |
2020 Q1 | 824.37 Million USD | -3.85% |
2020 Q2 | 807.68 Million USD | -2.03% |
2020 Q3 | 812.01 Million USD | 0.54% |
2020 FY | 826.84 Million USD | -3.56% |
2019 FY | 857.39 Million USD | -2.63% |
2019 Q4 | 857.39 Million USD | -4.09% |
2019 Q2 | 915.06 Million USD | 12.64% |
2019 Q1 | 812.39 Million USD | -7.74% |
2019 Q3 | 893.96 Million USD | -2.31% |
2018 Q1 | 867.61 Million USD | -3.45% |
2018 FY | 880.59 Million USD | -2.01% |
2018 Q4 | 880.59 Million USD | 2.92% |
2018 Q3 | 855.64 Million USD | -1.64% |
2018 Q2 | 869.91 Million USD | 0.27% |
2017 Q1 | 441.75 Million USD | -5.92% |
2017 FY | 898.65 Million USD | 91.38% |
2017 Q4 | 898.65 Million USD | 0.42% |
2017 Q3 | 894.89 Million USD | 64.92% |
2017 Q2 | 542.63 Million USD | 22.84% |
2016 Q1 | 442.53 Million USD | -5.96% |
2016 FY | 469.55 Million USD | -0.22% |
2016 Q4 | 469.55 Million USD | -3.43% |
2016 Q3 | 486.21 Million USD | -2.59% |
2016 Q2 | 499.12 Million USD | 12.79% |
2015 Q3 | 499.24 Million USD | -7.79% |
2015 Q1 | 435.54 Million USD | -9.92% |
2015 Q2 | 541.39 Million USD | 24.3% |
2015 FY | 470.57 Million USD | -2.68% |
2015 Q4 | 470.57 Million USD | -5.74% |
2014 Q4 | 483.52 Million USD | 40.4% |
2014 Q3 | 344.38 Million USD | -7.59% |
2014 Q2 | 372.65 Million USD | 31.88% |
2014 Q1 | 282.57 Million USD | -4.84% |
2014 FY | 483.52 Million USD | 62.83% |
2013 Q4 | 296.95 Million USD | 0.0% |
2013 Q1 | - USD | 0.0% |
2013 FY | 296.95 Million USD | 11.81% |
2012 FY | 265.58 Million USD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
uniQure N.V. | 831.68 Million USD | 49.076% |
Agios Pharmaceuticals, Inc. | 937.11 Million USD | 54.805% |
Amicus Therapeutics, Inc. | 777.88 Million USD | 45.553% |
Atara Biotherapeutics, Inc. | 165.5 Million USD | -155.903% |
bluebird bio, Inc. | 619.16 Million USD | 31.596% |
Cara Therapeutics, Inc. | 125.84 Million USD | -236.551% |
Imunon, Inc. | 21.91 Million USD | -1832.328% |
Editas Medicine, Inc. | 499.15 Million USD | 15.15% |
IQVIA Holdings Inc. | 26.68 Billion USD | 98.413% |
Mettler-Toledo International Inc. | 3.35 Billion USD | 87.378% |
Myriad Genetics, Inc. | 1.19 Billion USD | 64.668% |
Neurocrine Biosciences, Inc. | 3.25 Billion USD | 86.974% |
Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 69.941% |
Verastem, Inc. | 149.71 Million USD | -182.884% |
Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 99.477% |
Waters Corporation | 4.62 Billion USD | 90.846% |
Thermo Fisher Scientific Inc. | 98.72 Billion USD | 99.571% |
Biogen Inc. | 26.84 Billion USD | 98.422% |
Nektar Therapeutics | 398.03 Million USD | -6.405% |
Perrigo Company plc | 10.8 Billion USD | 96.082% |
Dynavax Technologies Corporation | 997.09 Million USD | 57.524% |
Illumina, Inc. | 10.11 Billion USD | 95.811% |
Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -1398.03% |
Iovance Biotherapeutics, Inc. | 780.35 Million USD | 45.726% |
Heron Therapeutics, Inc. | 222.5 Million USD | -90.345% |
Unity Biotechnology, Inc. | 65.69 Million USD | -544.739% |
BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 93.81% |
Sangamo Therapeutics, Inc. | 165.32 Million USD | -156.187% |
Evolus, Inc. | 188.99 Million USD | -124.092% |
Adicet Bio, Inc. | 207.29 Million USD | -104.312% |
Aclaris Therapeutics, Inc. | 197.4 Million USD | -114.548% |
Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 98.72% |
Esperion Therapeutics, Inc. | 205.79 Million USD | -105.8% |
Agilent Technologies, Inc. | 10.76 Billion USD | 96.065% |
OPKO Health, Inc. | 2.01 Billion USD | 78.947% |
Homology Medicines, Inc. | 47.05 Million USD | -800.034% |
Geron Corporation | 394.07 Million USD | -7.474% |
Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 88.941% |
Exelixis, Inc. | 2.94 Billion USD | 85.606% |
Viking Therapeutics, Inc. | 368.49 Million USD | -14.936% |
Anavex Life Sciences Corp. | 154.38 Million USD | -174.331% |
Intellia Therapeutics, Inc. | 1.3 Billion USD | 67.445% |
Zoetis Inc. | 14.28 Billion USD | 97.035% |
Axsome Therapeutics, Inc. | 588.23 Million USD | 28.0% |
Abeona Therapeutics Inc. | 64 Million USD | -561.743% |
Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 98.137% |
Kala Pharmaceuticals, Inc. | 55.94 Million USD | -656.991% |
Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 85.835% |
Sarepta Therapeutics, Inc. | 3.26 Billion USD | 87.027% |
Corcept Therapeutics Incorporated | 621.51 Million USD | 31.856% |
Halozyme Therapeutics, Inc. | 1.73 Billion USD | 75.565% |
Blueprint Medicines Corporation | 1.04 Billion USD | 59.635% |
Insmed Incorporated | 1.32 Billion USD | 68.152% |
TG Therapeutics, Inc. | 329.58 Million USD | -28.503% |
Incyte Corporation | 6.78 Billion USD | 93.755% |
Emergent BioSolutions Inc. | 1.83 Billion USD | 76.918% |